Straub et al., 2011b
Human evidence is absent: every in-vivo study published to date is rodent, and no NNMT inhibitor is approved anywhere
A recent review found that the benefits seen in some studies are likely due to the positive effects on the liver through the gut-liver-brain axis.[ref] Depression: M any patients with treatment-resistant depression have low acetyl-L-carnitine levels
Obsessive compulsive disorder
Clinical studies in patients with cardiac dysfunction have documented improved cardiac output, enhanced left ventricular ejection fraction, and reduced markers of cardiac stress following Hexarelin administration
Start low, go slow For any new peptide: Start at lowest effective dose Assess tolerance for 1-2 weeks Increase gradually if needed Don't rush to maximum dose Example progression: BPC-157: Start 250mcg 2x daily, can increase to 500mcg 2x daily if needed CJC/Ipa: Start 200mcg each, can increase to 300mcg if no sides Monitor for side effects Common across peptides: Injection site reactions (redness, swelling) Headaches (especially GH peptides initially) Water retention (GH peptides, GLP-1s) Nausea (GLP-1s, Melanotan II) When to stop: Severe allergic reaction (hives, difficulty breathing) Persistent severe side effects Unexplained symptoms Lack of improvement after reasonable trial Get baseline and follow-up bloodwork Before starting peptides: Basic metabolic panel Liver and kidney function Thyroid panel Relevant hormones (testosterone, IGF-1, etc.) During use: Follow-up testing every 3-4 months Monitor markers relevant to your peptides Adjust protocols based on results Legal and regulatory awareness Understand status: FDA-approved peptides require prescription Research peptides are gray area (legal to possess, not approved for human use) Athletic drug testing includes most peptides (WADA banned) See our are peptides legal guide for complete regulatory information
